Published in JAMA on September 22, 2004
Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) (2010) 2.86
Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology (2009) 2.75
Risk of pancreatic cancer in families with Lynch syndrome. JAMA (2009) 2.32
Family history of melanoma and Parkinson disease risk. Neurology (2009) 2.25
Confirmation of family cancer history reported in a population-based survey. J Natl Cancer Inst (2011) 2.13
The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. J Hepatol (2008) 2.02
Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine. CA Cancer J Clin (2011) 1.90
Development and validation of a colon cancer risk assessment tool for patients undergoing colonoscopy. Am J Gastroenterol (2009) 1.62
Very high incidence of familial colorectal cancer in Newfoundland: a comparison with Ontario and 13 other population-based studies. Fam Cancer (2007) 1.39
Population-based, case-control-family design to investigate genetic and environmental influences on melanoma risk: Australian Melanoma Family Study. Am J Epidemiol (2009) 1.27
Prospective study of family history and colorectal cancer risk by tumor LINE-1 methylation level. J Natl Cancer Inst (2012) 1.24
Interviews with primary care physicians regarding taking and interpreting the cancer family history. Fam Pract (2008) 1.13
Colonoscopy screening in African Americans and Whites with affected first-degree relatives. Arch Intern Med (2008) 1.13
Screening patients with a family history of colorectal cancer. J Gen Intern Med (2007) 1.12
Mutation Spectrum and Risk of Colorectal Cancer in African American Families with Lynch Syndrome. Gastroenterology (2015) 1.09
Family history of cancer and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Int J Cancer (2010) 1.07
Gastric cancer in individuals with Li-Fraumeni syndrome. Genet Med (2011) 1.05
Prevalence and healthcare actions of women in a large health system with a family history meeting the 2005 USPSTF recommendation for BRCA genetic counseling referral. Cancer Epidemiol Biomarkers Prev (2013) 1.05
Primary care physicians' use of family history for cancer risk assessment. BMC Fam Pract (2010) 1.04
Diagnosis and management of hereditary colorectal cancer syndromes: Lynch syndrome as a model. CMAJ (2009) 1.03
Family history of colorectal cancer: a determinant of advanced adenoma stage or adenoma multiplicity? Int J Cancer (2009) 1.01
Disease-specific prospective family study cohorts enriched for familial risk. Epidemiol Perspect Innov (2011) 1.01
The correlation between a family history of colorectal cancer and survival of patients with colorectal cancer. Fam Cancer (2009) 1.01
Early initiation of colorectal cancer screening in individuals with affected first-degree relatives. J Gen Intern Med (2007) 1.00
Population-based estimates of the relation between breast cancer risk, tumor subtype, and family history. Breast Cancer Res Treat (2008) 1.00
Familial relative risks for breast cancer by pathological subtype: a population-based cohort study. Breast Cancer Res (2010) 1.00
Frequency of extracolonic tumors in Brazilian families with Lynch syndrome: analysis of a hereditary colorectal cancer institutional registry. Fam Cancer (2010) 0.99
A review of African American-white differences in risk factors for cancer: prostate cancer. Cancer Causes Control (2010) 0.99
Family history and risk of breast cancer: nurses' health study. Breast Cancer Res Treat (2012) 0.97
The updated Swedish family-cancer database used to assess familial risks of prostate cancer during rapidly increasing incidence. Hered Cancer Clin Pract (2006) 0.95
Racial differences in prostate cancer screening by family history. Ann Epidemiol (2008) 0.94
Familial risks for nerve, nerve root and plexus disorders in siblings based on hospitalisations in Sweden. J Epidemiol Community Health (2007) 0.94
Genetic counseling for patients and families with hereditary breast and ovarian cancer in a developing Asian country: an observational descriptive study. Fam Cancer (2011) 0.93
Self-reported chemicals exposure, beliefs about disease causation, and risk of breast cancer in the Cape Cod Breast Cancer and Environment Study: a case-control study. Environ Health (2010) 0.93
Personalized medicine and access to health care: potential for inequitable access? Eur J Hum Genet (2012) 0.92
Perceived familiarity with and importance of family health history among a medically underserved population. J Community Genet (2012) 0.91
A population-based cross-sectional study of colorectal cancer screening practices of first-degree relatives of colorectal cancer patients. BMC Cancer (2013) 0.91
Health behaviors and cancer screening among Californians with a family history of cancer. Genet Med (2012) 0.89
Family history of cancer and risk of sporadic differentiated thyroid carcinoma. Cancer (2011) 0.89
Coherence and completeness of population-based family cancer reports. Cancer Epidemiol Biomarkers Prev (2010) 0.89
Missed opportunities: family history and behavioral risk factors in breast cancer risk assessment among a multiethnic group of women. J Gen Intern Med (2007) 0.89
Specifying exposure classification parameters for sensitivity analysis: family breast cancer history. Clin Epidemiol (2009) 0.89
Adherence to breast and ovarian cancer screening recommendations for female relatives from the Ontario site of the Breast Cancer Family Registry. Eur J Cancer Prev (2011) 0.87
Recruiting women for a study on perceived risk of cancer: influence of survey topic salience and early versus late response. Prev Chronic Dis (2013) 0.87
Performance of PREMM(1,2,6), MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases. Genet Med (2012) 0.87
Policy implications of early onset breast cancer among Mexican-origin women. Cancer (2011) 0.86
Racial and ethnic variations in the effects of family history of colorectal cancer on screening compliance. Gastroenterology (2013) 0.86
Individual- and provider-level factors associated with colorectal cancer screening in accordance with guideline recommendation: a community-level perspective across varying levels of risk. BMC Public Health (2013) 0.86
Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis. BMC Cancer (2007) 0.84
Validation of family cancer history data in high-risk families: the influence of cancer site, ethnicity, kinship degree, and multiple family reporters. Am J Epidemiol (2015) 0.84
The HOXB13 G84E Mutation Is Associated with an Increased Risk for Prostate Cancer and Other Malignancies. Cancer Epidemiol Biomarkers Prev (2015) 0.84
Cancer Visibility among Iranian Familial Networks: To What Extent Can We Rely on Family History Reports? PLoS One (2015) 0.83
Tailored information increases patient/physician discussion of colon cancer risk and testing: The Cancer Risk Intake System trial. Prev Med Rep (2016) 0.83
Adequacy of family history taking in ovarian cancer patients: a population-based study. Fam Cancer (2012) 0.82
Familial risk for chronic disease and intent to share family history with a health care provider among urban Appalachian women, southwestern Ohio, 2007. Prev Chronic Dis (2009) 0.81
Family history of cancer and malignant germ cell tumors in children: a report from the Children's Oncology Group. Cancer Causes Control (2009) 0.80
Can the cardiovascular family history reported by our patients be trusted? The Norwegian Stroke in the Young Study. Eur J Neurol (2015) 0.80
Do people really know what makes a family history of cancer? Health Expect (2012) 0.80
Racial and Ethnic Disparities in Colonoscopic Examination of Individuals With a Family History of Colorectal Cancer. Clin Gastroenterol Hepatol (2015) 0.80
Patient-reported hereditary breast and ovarian cancer in a primary care practice. J Community Genet (2013) 0.80
Impact of familial risk factors on management and survival of early-onset breast cancer: a population-based study. Br J Cancer (2006) 0.80
Recalibration of the Gail model for predicting invasive breast cancer risk in Spanish women: a population-based cohort study. Breast Cancer Res Treat (2013) 0.80
Characteristics associated with genetic counseling referral and BRCA1/2 testing among women in a large integrated health system. Genet Med (2014) 0.79
Influence of a family history of breast and/or ovarian cancer on breast cancer outcomes. Exp Ther Med (2011) 0.79
Mismatch repair protein expression in colorectal cancer. J Gastrointest Oncol (2013) 0.79
Breast cancer in the young: role of the geneticist. J Thorac Dis (2013) 0.78
Family history of breast and ovarian cancer and triple negative subtype in hispanic/latina women. Springerplus (2014) 0.78
An internal performance assessment of CancerGene Connect: an electronic tool to streamline, measure and improve the genetic counseling process. J Genet Couns (2014) 0.78
Towards personalized screening: Cumulative risk of breast cancer screening outcomes in women with and without a first-degree relative with a history of breast cancer. Int J Cancer (2015) 0.78
Family history of cancer and non-malignant diseases and risk of childhood acute lymphoblastic leukemia: a Children's Oncology Group Study. Cancer Epidemiol (2011) 0.78
Familial clustering of breast and prostate cancer and risk of postmenopausal breast cancer in the Women's Health Initiative Study. Cancer (2015) 0.77
Family history of pancreatic cancer in a high-risk cancer clinic: implications for risk assessment. J Genet Couns (2008) 0.77
Risk of other cancers in individuals with a family history of pancreas cancer. J Gastrointest Cancer (2007) 0.77
High accuracy of family history of melanoma in Danish melanoma cases. Fam Cancer (2015) 0.76
Family history of cancer and tobacco exposure in index cases of pancreatic ductal adenocarcinoma. J Oncol (2011) 0.76
Family history of skin cancer is associated with early-onset basal cell carcinoma independent of MC1R genotype. Cancer Epidemiol (2015) 0.76
Risk of breast cancer not increased in translocation 11;22 carriers: analysis of 80 pedigrees. Am J Med Genet A (2010) 0.76
History of upper gastrointestinal cancers in relatives: a community-based estimate. Gastroenterol Hepatol Bed Bench (2012) 0.75
Put the Family Back in Family Health History: A Multiple-Informant Approach. Am J Prev Med (2017) 0.75
Randomized trial finds that prostate cancer genetic risk score feedback targets prostate-specific antigen screening among at-risk men. Cancer (2016) 0.75
Beliefs about optimal age and screening frequency predict breast screening adherence in a prospective study of female relatives from the Ontario site of the Breast Cancer Family Registry. BMC Public Health (2012) 0.75
Validation of an online questionnaire for identifying people at risk of familial and hereditary colorectal cancer. Fam Cancer (2015) 0.75
Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention. Front Oncol (2016) 0.75
Selecting Quality Service Dogs: Part 1: Morphological and Health Considerations. APDT Chron Dog (2015) 0.75
Cognitive and affective influences on perceived risk of ovarian cancer. Psychooncology (2014) 0.75
Familial risk of non-Hodgkin lymphoma by sex, relationship, age at diagnosis and histology: a joint study from five Nordic countries. Leukemia (2015) 0.75
Family history of cancer and childhood rhabdomyosarcoma: a report from the Children's Oncology Group and the Utah Population Database. Cancer Med (2015) 0.75
Family History of Cancer in Relation to Breast Cancer Subtypes in African American Women. Cancer Epidemiol Biomarkers Prev (2015) 0.75
SISE matters: the sum of information on seventy-yr-old equivalents measures pedigree information content when assessing the risk of HNPCC in a family. Fam Cancer (2005) 0.75
Family history and risk of breast cancer: an analysis accounting for family structure. Breast Cancer Res Treat (2017) 0.75
Uncertainty quantification in breast cancer risk prediction models using self-reported family health history. J Clin Transl Sci (2017) 0.75
Development of an integrated support system for hereditary cancer and its impact on gynecologic services. Int J Clin Oncol (2013) 0.75
Impact of a family history of prostate cancer on clinicopathologic outcomes and survival following radical prostatectomy. World J Urol (2015) 0.75
Prevalence and clinicopathologic/molecular characteristics of mismatch repair-deficient colorectal cancer in the under-50-year-old Japanese population. Surg Today (2017) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol (2012) 5.16
ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov (2011) 3.27
American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. J Clin Oncol (2014) 3.07
High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol (2007) 2.99
Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol (2007) 2.93
Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) (2010) 2.86
Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol (2010) 2.84
Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol (2008) 2.78
Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology (2009) 2.75
Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA (2006) 2.73
Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology (2012) 2.69
International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol (2012) 2.44
Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res (2002) 2.33
Risk of pancreatic cancer in families with Lynch syndrome. JAMA (2009) 2.32
Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut (2012) 2.17
Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol (2005) 2.07
Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol Biomarkers Prev (2006) 2.04
Obesity increases the risks of diverticulitis and diverticular bleeding. Gastroenterology (2008) 2.01
Mutant TP53 in duodenal samples of pancreatic juice from patients with pancreatic cancer or high-grade dysplasia. Clin Gastroenterol Hepatol (2012) 1.99
Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol (2010) 1.98
The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology (2010) 1.88
Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology. J Natl Cancer Inst (2013) 1.80
Physician assessment of family cancer history and referral for genetic evaluation in colorectal cancer patients. Clin Gastroenterol Hepatol (2004) 1.76
Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk. Genet Med (2011) 1.70
Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps. Cancer Prev Res (Phila) (2012) 1.65
Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol (2011) 1.63
Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. J Mol Diagn (2004) 1.62
Development and validation of a colon cancer risk assessment tool for patients undergoing colonoscopy. Am J Gastroenterol (2009) 1.62
Knowledge of quality performance measures associated with endoscopy among gastroenterology trainees and the impact of a web-based intervention. Gastrointest Endosc (2012) 1.59
Risk factors for mortality in lower intestinal bleeding. Clin Gastroenterol Hepatol (2008) 1.55
Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol (2005) 1.50
Chromoendoscopy detects more adenomas than colonoscopy using intensive inspection without dye spraying. Cancer Prev Res (Phila) (2008) 1.47
Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology (2010) 1.46
Nut, corn, and popcorn consumption and the incidence of diverticular disease. JAMA (2008) 1.46
The comprehensiveness of family cancer history assessments in primary care. Community Genet (2007) 1.42
Impact of preoperative staging and chemoradiation versus postoperative chemoradiation on outcome in patients with rectal cancer: a decision analysis. J Natl Cancer Inst (2004) 1.42
Hereditary colorectal cancer syndromes. Cancer Causes Control (2005) 1.40
Factors associated with enrollment in cancer genetics research. Cancer Epidemiol Biomarkers Prev (2006) 1.31
Hereditary pancreatic cancer. Gastroenterology (2010) 1.31
Cancer risk assessment: quality and impact of the family history interview. Am J Prev Med (2004) 1.30
Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol (2006) 1.29
Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol (2007) 1.29
Timing of colonoscopy: impact on length of hospital stay in patients with acute lower intestinal bleeding. Am J Gastroenterol (2003) 1.28
Colorectal cancers with microsatellite instability display unique miRNA profiles. Clin Cancer Res (2011) 1.27
F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA (2008) 1.26
Sharing genetic test results in Lynch syndrome: communication with close and distant relatives. Clin Gastroenterol Hepatol (2008) 1.20
Early predictors of severity in acute lower intestinal tract bleeding. Arch Intern Med (2003) 1.19
Phenotype comparison of MLH1 and MSH2 mutation carriers in a cohort of 1,914 individuals undergoing clinical genetic testing in the United States. Cancer Epidemiol Biomarkers Prev (2008) 1.16
Validation and extension of the PREMM1,2 model in a population-based cohort of colorectal cancer patients. Gastroenterology (2007) 1.16
Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer (2010) 1.15
Elevated risk of prostate cancer among men with Lynch syndrome. J Clin Oncol (2013) 1.14
Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. Oncologist (2010) 1.14
Comprehensive molecular analysis of mismatch repair gene defects in suspected Lynch syndrome (hereditary nonpolyposis colorectal cancer) cases. Cancer Res (2009) 1.14
Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol (2010) 1.12
Enhanced retrieval of DNA from human fecal samples results in improved performance of colorectal cancer screening test. J Mol Diagn (2004) 1.11
Missed adenomas during colonoscopic surveillance in individuals with Lynch Syndrome (hereditary nonpolyposis colorectal cancer). Cancer Prev Res (Phila) (2008) 1.11
Determinants of colorectal cancer screening in women undergoing mammography. Am J Gastroenterol (2003) 1.10
A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. Cancer Invest (2011) 1.09
Colorectal cancer in young adults. Dig Dis Sci (2014) 1.08
Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. Gastroenterology (2006) 1.08
Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Hum Mutat (2011) 1.07
Inherited colorectal cancer syndromes. Cancer J (2011) 1.06
Gastric cancer in individuals with Li-Fraumeni syndrome. Genet Med (2011) 1.05
Validation of a clinical prediction rule for severe acute lower intestinal bleeding. Am J Gastroenterol (2005) 1.04
Prevalence and predictors of appropriate colorectal cancer surveillance in Lynch syndrome. Am J Gastroenterol (2010) 1.03
Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma (2009) 1.03
Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer (2008) 1.03
Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. Clin Adv Hematol Oncol (2012) 1.03
The impact of family history of diabetes on glucose testing and counseling behavior in primary care. Diabetes Care (2004) 1.02
Genetic testing in gastroenterology: Lynch syndrome. Best Pract Res Clin Gastroenterol (2009) 1.02
A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res (2009) 1.01
Colon cancer screening strategies. Curr Opin Gastroenterol (2005) 0.98
Predictors of utilization of early colonoscopy vs. radiography for severe lower intestinal bleeding. Gastrointest Endosc (2005) 0.98
Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial. Clin Genitourin Cancer (2007) 0.97
Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. Oncologist (2009) 0.97
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol (2015) 0.97
A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer. Eur J Cancer (2010) 0.97
Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer. Clin Breast Cancer (2009) 0.96
Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry. JAMA Oncol (2015) 0.96
Colorectal cancer risk perception on the basis of genetic test results in individuals at risk for Lynch syndrome. J Clin Oncol (2009) 0.96
Colorectal cancer screening: prevalence among low-income groups with health insurance. Health Aff (Millwood) (2009) 0.96
Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer. Clin Breast Cancer (2009) 0.95
Recently identified colon cancer predispositions: MYH and MSH6 mutations. Semin Oncol (2007) 0.94
Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndrome. Gynecol Oncol (2012) 0.94
A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer. Clin Breast Cancer (2008) 0.94
Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointest Endosc (2014) 0.94
Intraductal papillary mucinous neoplasm of the pancreas with loss of mismatch repair in a patient with Lynch syndrome. Am J Surg Pathol (2009) 0.94
Risk assessment, genetic testing, and management of Lynch syndrome. J Natl Compr Canc Netw (2010) 0.92
Screening patients with colorectal cancer for Lynch syndrome: what are we waiting for? J Clin Oncol (2012) 0.92